Category: Accesswire

Company Confirms Structured Evaluation Underway as Engineering Progress Accelerates Path to AHRI, ENERGY STAR® Certification and 2H 2026 Revenue

WEST SENECA, NY / ACCESS Newswire / February 12, 2026 / Worksport Ltd. (NASDAQ:WKSP) (“Worksport” or the “Company”), a U.S.-based technology and manufacturing company focused on clean energy solutions and automotive accessories for consumer and reseller channels, today provided an operational update on its energy subsidiary, Terravis Energy, as it advances the Aetherlux™ Pro heat pump ZeroFrost™ anti-frosting technology toward third-party validation, certification, and early commercialization.

Management believes Zerofrost represents a materially undervalued intellectual property asset within Worksport’s overall corporate footprint and a meaningful driver of exponential long-term enterprise value that is not currently reflected in the Company’s market valuation. The global heat-pump market is expected to exceed $150 billion by 2030. Growing third-party validation efforts and government-level interest underscore Zerofrost’s potential to reshape performance standards within the cold-climate heat-pump market.

Accelerating Momentum Across Government, Certification and Commercialization

Government Evaluation Underway

• Worksport confirmed that a large government entity is actively monitoring upcoming laboratory performance results as part of an internal evaluation process. While no procurement decisions have been made, management expects validated test data to accelerate discussions related to potential deployment and large-scale supply arrangements across various regions.

Certification Timeline Moves Ahead of Schedule

• Based on recent engineering progress and manufacturing coordination, the Aetherlux heat pump with ZeroFrost technology is now expected to enter formal certification processes ahead of prior expectations. Targeted certifications (within 2026) include AHRI performance standards, ENERGY STAR® qualification, and other leading industry requirements necessary for broad North American deployment.

Clear Line of Sight to Revenue

• Following completion of certification and early commercial deployments, the Company expects Aetherlux to become a revenue-generating product in the second half of 2026, marking a transition from development to commercial execution. In-bound dealer interest remains strong.

Manufacturing Transition to Validation Phase

• Manufacturing prototypes are scheduled to arrive in February 2026 and will be delivered shortly thereafter to testing partners. During the first half of 2026, the technology is expected to undergo structured performance and reliability evaluation at two government-affiliated laboratories, supporting certification and commercial readiness.

Commercial Organization Build-Out

• Terravis Energy’s inbound sales funnel continues to grow. To support market entry and long-term growth, Terravis plans to further formalize its sales organization and expects to begin onboarding senior commercial leadership, including a Senior Vice President of Sales, as certification milestones approach.

Additional Background on Aetherlux Progression

Investors and stakeholders are encouraged to review the following milestones outlining why Aetherlux is attracting increasing industry attention and how it may influence future market standards:

1. February 2025: Initial Product Reveal

2. October 2025: Award from U.S. Department of Energy National Renewable Energy Laboratory

3. January 2026: Manufacturer selected; commercialization pathway established; the Aetherlux Advantage

Interested in speaking with the Aetherlux team? Use: Aetherlux Contact Us.

For all future updates, join Worksport’s Newsletter.

Contacts
Investor Relations, Worksport Ltd.
T: 1 (888) 554-8789-128
W: investors.worksport.com
W: www.worksport.com
E: investors@worksport.com

Connect With Worksport Chief Executive Officer Steven Rossi

Steven Rossi X (Twitter)

Steven Rossi LinkedIn

About Worksport

Worksport Ltd. (NASDAQ:WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport’s hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy’s website is terravisenergy.com.

Connect With Worksport

Please follow the Company’s social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram, the links of which are links to external third-party websites, as well as sign up for the Company’s newsletters at investors.worksport.com.

Social Media Disclaimer

The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company. Investors and others should note that the Company announces material financial information to our investors using our investor relations website, press releases, Securities and Exchange Commission (SEC”) filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media. The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “scheduled,” “expect,” “future,” “intend,” “plan,” “project,” “envisioned,” “should,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial situation may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; and (iv) competition from other producers of similar products. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

SOURCE: Worksport Ltd.

View the original press release on ACCESS Newswire

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for Orphan Drug Designation (ODD) for “NV-387 as a Treatment for MPox” with the US FDA Office of Orphan Products Development (OOPD).

If approved, orphan drug designation will qualify NanoViricides for incentives including:

• Tax credits for qualified clinical trials;

• Exemption from certain user fees;

• Potential seven years of market exclusivity after approval;

according to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products).

“NV-387, as an effective drug would be an important tool to fight MPox in the USA and worldwide, when approved after clinical trials,” said Anil R. Diwan, PhD, adding, “MPXV clade IIb is endemic in the USA. Further, the more contagious MPXV Clade Ia/Ib continues to simmer in Africa and is mutating, posing a potential global pandemic threat.”

WHO had declared a “Public Health Emergency of International Concern” (PHEIC) for MPox in 2022 due to the spread of MPXV Clade II into Western countries, ending it about a year later. A new PHEIC was declared by WHO again in August, 2024, due to the spread of MPox Clade Ia/Ib in African region, ending it in September, 2025. However, the Africa CDC has continued the declaration of the MPox pandemic in African Region as Public Health Emergency of Continental Security (“PHECS”), due to continued spread of the MPXV virus.

MPox disease is caused by infection with MPXV (Monkeypox Virus) virus. While earlier MPXV infections were related to zoonotic (i.e. from animals) transmission to humans, the virus has evolved to a highly contagious form, MPXV Clade Ib, in recent years with continuous human-to-human transmission. MPXV is closely related to Variola virus that causes Smallpox in humans. Smallpox is a far more severe and lethal disease compared to MPox. Smallpox was globally eradicated by 1980 by an aggressive vaccination campaign with an effective vaccine that provides lifelong immunity. This success is founded in the fact that Smallpox is restricted to humans and has no animal reservoirs, unlike MPox which has many animal reservoirs. Smallpox continues to be a bio-terrorism concern.

There is no approved drug for the treatment of MPox. Tecovirimat (TPOXX®, SIGA) and brincidofovir (TEMBEXA®, EBS) were approved by the US FDA for Smallpox, both under the “Animal Rule”. Tecovirimat has failed to show any clinical effectiveness, and did not show any viral load reduction benefit either, over standard of care in a clinical trial for treatment of MPXV infections¹. Mutants resistant to tecovirimat were found to be generated in some cases. Brincidofovir treatment resulted in drug-induced liver disease in three out of three treated MPox patients resulting in cessation of therapy, and did not show any effectiveness in these patients according to a peer reviewed “retrospective observational study” also called “non-randomized study”². In spite of this, a clinical trial of brincidofovir for treating MPox was initiated under an international coalition led by US CDC and first patient was dosed around January 2025 in this “MOSA” clinical trial³. The topline results from this clinical trial regarding safety and efficacy were anticipated by CY Q2 (i.e. June, 2025). We have not found any press releases announcing any such results.

The orthopoxviruses can escape both small chemical drugs, tecovirimat and brincidofovir, by mutations, according to peer reviewed scientific articles⁴.

MPXV has continued to mutate in the African region. Mutants resistant to the JYNNEOS® Smallpox vaccine that was fielded to control the spread of MPXV Clade Ia/Ib have been found. The antibody response to MPXV from the JYNNEOS vaccine was found to be poor and short-lived⁵.

The above factors clearly highlight the need for an effective therapeutic for the treatment of MPOX.

NV-387 has shown strong effectiveness in a mouse model of dermal lethal infection of ectromelia, an orthopoxvirus closely related to viruses that cause smallpox and mpox. NV-387 has successfully completed a Phase I human clinical trial demonstrating safety and tolerability in healthy adults with no reported adverse events. Therefore the Company believes that NV-387 is a viable clinical candidate for the treatment of MPox.

In the USA, MPOX incidence rate was approximately 2,042 cases in 2025, well below 200,000 cases⁶. Thus NV-387 for the Treatment of MPox qualifies for Orphan Drug Designation.

NanoViricides employed the expert services of Only Orphans Cote, LLC, (“OOC”) a regulatory consultant firm founded by Dr. Timothy Cote, for developing the ODD application. Dr. Timothy Cote previously served as the Director of US FDA Office of Orphan Products Development (OOPD), and has intimate knowledge of the laws, rules, and regulations, governing orphan drugs, and the potential benefits to the Drug Sponsors.

NV-387 is an unusually broad-spectrum antiviral drug that has demonstrated strong effectiveness in relevant animal models of multiple human viral infections. These include RSV, COVID, Influenza, Mpox, Smallpox, and Measles.

Viral resistance to NV-387 is unlikely because this drug mimics specific cell-side features that these viruses continue to employ to effectively infect human host cells, despite how much they may change in the field. In contrast, viruses mutations readily result in making traditional vaccines, antibodies, and small chemical drugs ineffective.

Further, NV-387 is a complete chemical nanomachine that completes the task of binding to, engulfing, and destroying virus particles without any dependence on the human immune system.

These factors make NV-387 unique in the field of antiviral drugs and vaccines.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide^™ class of drug candidates and the nanoviricide^™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour^® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

Eight homes arrive by crane, bringing Santa Rosa’s first modular neighborhood to life.

SANTA ROSA, CA / ACCESS Newswire / February 12, 2026 / Villa, a California-based innovator in scalable offsite homebuilding, has installed the first phase of homes to Acacia Village, a new 25-home neighborhood in Santa Rosa’s Rincon Valley. When complete, Acacia Village will stand as the region’s first single-family “pocket neighborhood” built with offsite construction. A site that sat empty in early December is now on track to welcome its first residents soon, a transformation made possible by the speed of offsite construction.

Acacia Village is the first of several planned Neighborhoods by Villa™, a new generation of infill communities designed to deliver high-quality, design-forward homes at scale. Villa’s offsite construction process minimizes neighborhood disruption and shortens build timelines.

“With Acacia Village, we aim to show that offsite construction is a viable solution for infill housing, even in hard-to-build, high-cost areas like Northern California,” said Sean Roberts, CEO of Villa. “Each home reflects our belief that speed and precision can go hand in hand with craftsmanship and character. These homes demonstrate how modern offsite construction can be applied to single-family living without compromising aesthetics, quality, durability, or long-term value.”

Acacia Village will feature 25 Craftsman-style single-family homes with three- and four-bedroom floorplans, one- and two-story layouts, and private garages. All of the homes are built with energy efficiency in mind and are ENERGY STAR® certified. Priced from the mid-$700,000s, the homes pair timeless architecture with contemporary functionality and shared green spaces inspired by the Sonoma landscape.

Acacia Village is located in Rincon Valley, one of Santa Rosa’s most sought-after neighborhoods, offering proximity to top-rated schools, local parks, and scenic trails in Annadel State Park and Spring Lake. The area is served by the Rincon Valley Union School District, which has been celebrated for its high-performing elementary and middle schools. With convenient access to shopping, dining, and Highway 12, Rincon Valley strikes the perfect balance between tranquil residential life and connectivity to the rest of Sonoma County.

To learn more and view available floor plans, visit www.villahomes.com/neighborhoods/acacia-village.

About Villa

Villa is a next-generation homebuilding platform that applies modern offsite construction methods and technology to efficiently build much-needed housing. Villa’s mission is to be the easiest, fastest, and most cost-efficient way to build high-quality homes. By partnering with a wide network of offsite housing manufacturers that build home products to Villa’s designs and specifications, Villa acts as a technology-powered demand aggregation and fulfillment platform.

From discovery and feasibility to permitting, installation, project management, and post-completion service, Villa offers a seamless, end-to-end customer experience. Villa also operates as a merchant homebuilder and principal developer with capital partners. For more about Villa, please visit http://villahomes.com/.

For Media Inquiries, Please Contact:

Mandy Menaker
press@villahomes.com

ENERGY STAR® is a registered trademark owned by the U.S. Environmental Protection Agency.

Villa Technologies, Inc. CSLB# 1077688 HCD#DL1564605 | Villa P1 Acacia Village, LLC HCD# DL1629355 | W Group DRE# 01795950

SOURCE: Villa Homes

View the original press release on ACCESS Newswire

Appointment strengthens ALT5’s Board with expertise across AI infrastructure, decentralized systems, and global technology governance

LAS VEGAS, NEVADA / ACCESS Newswire / February 12, 2026 / ALT 5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ:ALTS)(FRA:5AR1), a fintech company operating institutional-grade global payments, trading, and settlement infrastructure, today announced the appointment of Dr. Adel Elmessiry, Ph.D., as an independent member of its Board of Directors. Dr. Elmessiry accepted the appointment on January 29, 2026.

Dr. Elmessiry is an AI scientist, infrastructure architect, and technology policy contributor with deep expertise at the intersection of artificial intelligence, blockchain systems, and decentralized digital infrastructure. His appointment reflects ALT5’s continued focus on strengthening governance and strategic oversight as the Company expands its Board with leaders bringing complementary expertise across enterprise operations, emerging technologies, and global infrastructure.

Dr. Elmessiry currently serves as the Official United Nations Representative for the Creators Union of Arabs, where he contributes to global discussions on AI accessibility, digital sovereignty, and ethical technology governance. He is also the founder of multiple AI and blockchain initiatives focused on decentralized compute networks, tokenized infrastructure, and verifiable consensus mechanisms. In addition, he is a published academic author with peer-reviewed research in artificial intelligence and distributed systems and is involved with the International Conference on Blockchain and Cryptocurrency (ICBC), a leading academic forum advancing blockchain research and innovation.

“Dr. Elmessiry brings a rare combination of technical depth, global policy perspective, and entrepreneurial experience building decentralized infrastructure at scale,” said Tony Isaac, President and Chief Executive Officer of ALT5 Sigma. “As ALT5 continues to operate at the intersection of regulated financial infrastructure and emerging technologies, his insight will be invaluable in guiding the Company’s long-term strategy and governance.”

With a Ph.D. in Artificial Intelligence, Machine Learning, and Blockchain Systems, Dr. Elmessiry has advised and invested in technology companies across AI, Web3, and digital infrastructure, including serving as a limited partner in leading blockchain-focused investment funds. He has also held advisory and board roles supporting startup ecosystems, public institutions, and innovation initiatives globally.

“I am honored to join the Board of ALT5 Sigma at a time when financial infrastructure, digital assets, and AI systems are converging in meaningful ways,” said Dr. Elmessiry. “ALT5 is building critical infrastructure that emphasizes transparency, compliance, and scalability. I look forward to contributing to the Company’s mission and supporting its long-term growth.”

Dr. Elmessiry’s appointment further strengthens ALT5’s Board as the Company continues to scale its platform capabilities, expand its institutional relationships, and navigate an increasingly complex regulatory and technological landscape.

About ALT5 Sigma Corporation

ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech company with a strategic $WLFI digital asset treasury strategy initiative and established global payments, trading, and settlement infrastructure. Founded in 2018, the company leverages its blockchain infrastructure expertise and proven track record of processing over $8 billion in cryptocurrency transactions to optimize its digital asset treasury operations and capitalize on growing $WLFI ecosystem developments across retail platforms, payment integrations, and international market expansion.

Forward-looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the WLFI financing, ALT5’s accelerated growth in digital asset treasury operations, the value of ALT5’s $WLFI holdings, the positioning of the Company in the digital asset treasury sector, the profitability and prospective growth of ALT5’s platforms and business that are subject to risks that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion, and statements regarding the Company’s potential separation plans of its biotech business. Words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, the closing of the WLFI financing, changes in the value of $WLFI tokens, a downturn in the adoption of stable coins, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations

1-888-778-7091

SOURCE: ALT5 Sigma Corp

View the original press release on ACCESS Newswire

SAN BERNARDINO, CA / ACCESS Newswire / February 12, 2026 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) (Dateline or the Company) is pleased to report results from diamond core hole CM25-41 at its 100%-owned Colosseum Gold and Rare Earth Element (REE) Project in San Bernardino County, California. The hole was drilled in the northeast extension of the North Pipe breccia system, an area beyond the currently defined mineral resource boundary that has been progressively delineated through the Company’s 2025 drilling program.

CM25-41 intersected 149.65 metres grading 1.39 g/t Au from surface to end-of-hole, including a high-grade zone of 55.2m @ 2.83 g/t Au from surface. The hole terminated in mineralisation with the final bottom-of-hole sample returning approximately 1 g/t Au, confirming the gold-bearing breccia pipe remains open at depth.

Dateline’s Managing Director, Stephen Baghdadi, commented:

“Colosseum continues to deliver positive results as we work systematically across the project. This latest drilling advances our geological understanding and reinforces the view that there is further value to be unlocked beyond those areas already defined. We are progressing the next phase of work in a disciplined way, with the objective of determining how these results can translate into longer-mine life options for the project.”

Northeast Extension – Progressive Definition

The northeast extension of the North Pipe has been progressively defined through a series of reverse circulation (RC) and diamond core holes (DD) drilled during 2025. The latest result from CM25-41 adds further confidence to gold grades within this emerging zone and supports the continuity of mineralization along the northeast portion of the breccia system.

Key intercepts from the northeast extension drilling program reported to date include:

Hole	From (m)	To (m)	Length (m)	Au (g/t)	Comments
CM25-41	0.0	149.65	149.65	1.39	NEW – This release
Incl.	0.0	55.2	55.2	2.83	High-grade core
RC25-035	0.0	295.64	295.64	1.04	Reported 12 Jan 2026
Incl.			38.10	2.04
RC25-037	0.0	105.15	105.15	1.24	Reported 12 Jan 2026
Incl.			53.34	1.45
RC25-039	0.0	205.73	205.73	0.88	Reported 12 Jan 2026
Incl.			21.33	1.81
RC25-036	0.0	300.21	300.21	0.66	Reported 12 Jan 2026
Incl.			32.00	1.24
RC25-034	0.0	297.17	297.17	0.68	Reported 12 Jan 2026
Incl.			33.53	1.25

Note: Intercepts reported above a lower cut-off grade of 0.1 g/t Au. No upper cut-off grade has been applied. All lengths are downhole lengths. Previously reported results sourced from ASX announcement dated 12 January 2026.

CM25-41 ended in ore-grade mineralization, indicating drilling has not yet defined the limits of this system. With the larger diamond drill rigs now mobilizing, the Company intends to fully test the extent of this zone.

Dateline is working to determine if this newly defined northeast extension can extend the mine life beyond the approximately eight and a half-year open-pit operation outlined in the May 2025 Scoping Study. Any additional resources delineated in this section could potentially prolong the mine life, with the opportunity for an underground mining phase to follow after open-pit mining is completed.

Next Steps

To fully delineate the potential of the northeast extension, larger-capacity diamond core drill rigs will be used to:

• Test the deeper portions of the North Pipe breccia system, beyond the ~300m depth reached,

• Provide continuous core samples for detailed geological analysis,

• Better delineate the geometry and orientation of the breccia pipe at depth and along strike, and,

• Assist in the assessment of the Bankable Feasibility Study.

Resource Expansion and Mine Life Context

The Colosseum Gold-REE Project currently hosts a JORC 2012-compliant Mineral Resource of 27.1Mt @ 1.26 g/t Au for 1.1Moz, of which over 67% is classified as Measured and Indicated. The May 2025 Scoping Study outlined an open-pit operation with an initial mine life of approximately 8.5 years, generating an IRR of 61% at a gold price of US$2,900/oz.

The northeast extension drilling results reported herein and in previous announcements demonstrate gold mineralization extending beyond the current mineral resource boundary. The Company notes the intersected grades in the northeast extension area are higher than average mineral resource grade in several instances and the system remains open.

In particular, the presence of high-grade zones within the broader mineralized envelopes (for example, 55.2m @ 2.83 g/t Au within CM25-41) may present an opportunity for a follow-up underground mining phase to selectively extract higher-grade material after completion of open-pit operations, thereby potentially extending the productive life of the project.

The Company will continue to update the market as further results become available.

This press release has been authorized for release by the Board of Dateline Resources Limited.

For more information, please contact:

Stephen Baghdadi
Managing Director
+61 2 9375 2353

Andrew Rowell
Corporate & Investor Relations Manager
+61 400 466 226
a.rowell@dtraux.com
www.datelineresources.com.au

Follow Dateline on socials:
X – @Dateline_DTR
Truth Social – @dateline_resources
LinkedIn – dateline-resources
YouTube – @dateline.resources

About Dateline Resources Limited

Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.

The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.

On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.

The Colosseum is located less than 10km north of the Mountain Pass Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.

Dateline also owns 100% of the high-grade Argos Strontium Project, also located in San Bernardino County, California. Argos is reportedly the largest strontium deposit in the U.S. with previous celestite production grading 95%+ SrSO₄.

Forward-Looking Statements

This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behavior of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.

Competent Person Statement

Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr. Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr. Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr. Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.

Company Confirmations

The Company confirms it is not aware of any new information or data that materially affects the information included in the announcements dated 23 October 2024 with regard to the Colosseum MRE and 23 May 2025 with regard to Colosseum Project Economics. Similarly, the Company confirms that all material assumptions and technical parameters underpinning the estimates and the forecast financial information referred to in those previous announcements continue to apply and have not materially changed.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines

Ondansetron, currently sold under the brand name Zofran^®, was the 53rd most commonly prescribed medication in the U.S. in 2023

Global ondansetron market size valued at approximately $1.4 billion in 2023

ESTERO, FL / ACCESS Newswire / February 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled “A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof,” marks the first-ever sublingual powder delivery system for ondansetron-the active ingredient in Zofran^®. Aspire’s formulation is designed to provide rapid relief for patients suffering from nausea and vomiting induced by chemotherapy, radiation, or surgery.

Redefining Nausea Relief: IV Speed Without the Needle

Ondansetron is currently limited by a roughly 30-minute delay when taken as a tablet. NIH

Aspire’s sublingual platform is engineered to deliver:

• Near-Instant Absorption: Bypasses the gastrointestinal tract and first-pass metabolism, potentially reducing onset of action from 30 minutes to just minutes.

• Clinical Comparability: Designed to mirror the speed of intravenous (IV) administration without the need for hospital-based injections or professional assistance.

• Patient Compliance: Specifically addresses the “unmet need” for patients who cannot swallow tablets due to severe emesis (vomiting) or gastric irritation.

Strategic Market Positioning

• Significant and Growing Utilization: Ondansetron was the 53rd most prescribed medication in the U.S. in 2023, with over 12.5 million prescriptions, according to ClinCalc.

• Market Growth: The global ondansetron market is projected to grow from $1.4 billion (2023) to $2.4 billion by 2032, driven by rising cancer incidences and expanded surgical procedures, according to DATAINTELO.

• Accelerated Approval Path: Aspire intends to utilize the FDA’s 505(b)(2) regulatory pathway, which leverages existing safety data to streamline clinical development and reduce time-to-market.

CEO Commentary

“This product candidate exemplifies the real-world clinical benefits of our sublingual drug delivery technology, providing fast relief when minutes matter most. By making existing, trusted medications work better and faster, we aim to provide a treatment solution for anyone facing the debilitating effects of acute nausea-from chemotherapy side effects to post-operative recovery,” said Kraig Higginson, Interim CEO of Aspire.

About Zofran^® and Ondansetron
Zofran^®, developed by GlaxoSmithKline, was approved by the FDA in 1991, with a generic version approved in July 2007. Ondansetron is used to prevent nausea and vomiting that is caused by cancer medicines (chemotherapy) or radiation therapy. It is also used to prevent nausea and vomiting that may occur after surgery. Ondansetron works in the stomach to block the signals to the brain that cause nausea and vomiting.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events an developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

MIAMI BEACH, FLORIDA / ACCESS Newswire / February 12, 2026 / Diveroli Investment Group (“DIG”) today announced that it has filed a Schedule 13D with the U.S. Securities and Exchange Commission disclosing a significant ownership position in PetMed Express, Inc. (“PetMed” or the “Company”).

DIG believes PetMed’s current share price is materially disconnected from the Company’s intrinsic value. With multiple acquisition proposals on the table, significant hard assets on the balance sheet, no long-term debt, and a nationally recognized brand operating in a $165+ billion U.S. pet industry, DIG is calling on PetMed’s Board of Directors to act decisively in the best interests of all shareholders.

In late 2025, PetMed received multiple unsolicited, all-cash acquisition proposals at prices well above the current trading level, including a $4.25 per share proposal from Cardone Ventures and a $4.00 per share proposal from SilverCape Investments, underscoring the strategic value of the Company’s platform, brand, and customer base.

“With multiple cash proposals, it’s clearly an attractive target for acquirers,” said DIG Chief Investment Officer Aharon Diveroli. “When private capital is willing to pay 40% premiums, it’s incumbent on management to explain why shareholders should wait.”

Beyond the existing proposals, DIG believes the situation could attract additional interest. M&A research spanning 30 years shows that in 20-30% of unsolicited bid situations, a third-party ‘White Knight’ ultimately acquires the target at a higher price once valuation gaps become clear. PetMed’s nationally licensed pharmacy platform, fulfillment infrastructure, and established customer base may appeal to potential bluechip acquirers like Amazon, as well as experienced consolidators like Chewy and Tractor Supply, both of which have expanded through prior pet-focused acquisitions.

PetMed’s 184,000+ square foot headquarters and fulfillment center in Delray Beach, Florida – acquired in 2016 for $18.5 million – is a significant asset. South Florida industrial real estate has appreciated significantly since then, with the property now assessed at over $19.4 million according to Palm Beach County records. This asset alone represents approximately $0.92 per share, forming a meaningful part of the Company’s valuation floor.

At roughly $2.90-$3.00 per share, investors are assigning minimal value to PetMed’s operating business, brand, customer base, and licensed pharmacy platform – a clear case of market undervaluation during a transition period.

“Pet ownership and associated spending has shown durable growth across economic cycles” added DIG Chief Operating Officer Jonathan Berney. “U.S. expenditures grew annually at roughly 7-8% the past decade and are projected to surpass $150 billion in the next few years. Pet moms and dads continue to drive recurring demand.”

DIG intends to engage constructively with the Company’s board and management regarding strategic alternatives, governance, and actions to maximize shareholder value. DIG may also communicate with other shareholders and interested parties as appropriate.

About Diveroli Investment Group

Diveroli Investment Group (or “DIG”) is a Miami-based, family-run investment firm that pursues value creation through opportunities in public and private companies. The firm focuses on sectors where technological change, operational inflection points, or strategic under-appreciation create significant upside potential. Founded in 2025, the firm achieved a +385% first-year return on proprietary capital and is assessing the feasibility of accepting outside capital from select accredited investors later this year.

Investor & Media Relations
Avigail Diveroli, Communications Director
Diveroli Investment Group
Email: avigail@investdig.com
Website: www.investdig.com

Important Additional Information and Where to Find It

The views expressed in this press release reflect the personal opinions of the authors or speakers and are based solely on publicly available information believed to be reliable at the time of publication. This communication is not a recommendation to buy, sell or exchange any securities, and it does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any securities. Information about PetMed Express is available at the SEC’s website at www.sec.gov. We are not broker-dealers or registered investment advisors. Although we possess PETS shares, we may buy or sell shares at any time without notice.

Any statements about valuation, performance, or outlook are personal opinions and should not be construed as facts. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Compensation may have been provided to third parties involved in the creation or promotion of this content. All material is for informational and educational purposes only.

SOURCE: Diveroli Investment Group

Related Documents:

• sec.gov_Archives_edgar_data_1040130_000149315226006275_xslSCHEDULE_13D_X01_primary_doc.xml
• Investment Thesis (PETS)

View the original press release on ACCESS Newswire

HOUSTON, TX / ACCESS Newswire / February 12, 2026 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with 20,000 leasehold acres in the Permian Basin. The fields have a total of 750 producing and injection wells producing over 1,000 barrels of oil per day. Today, the Company announced it is increasing its hedging position in 2026 and 2027 to leverage future contracts to manage various risks.

Hedging programs are used in the oil industry by utilizing hedging contracts (or positions) to mitigate the risks of unfavorable price movement. Typically, the hedging position level is a balance of the percentage of current production compared to the cash requirements for operating expenses and debt service requirements. There are many types of hedging contracts. EON typically uses no-cost swaps (a set price per barrel), and no-cost collars (provides a range above and below a swap to take advantage of some potential upside at an amount that has a floor for the downside).

EON took advantage of higher oil price spikes in September 2025 and the last couple of weeks to lock in hedging contracts at favorable pricing. These recent contracts were all swaps and provide for an average price for oil of greater than $60.00 per barrel. EON has now established its hedging position at 60% of current oil production for the balance of 2026, and 50% for the first quarter of 2027. EON will continue to monitor oil prices to further enhance our hedging position as new production comes on line, and into the later quarters of 2027.

“There is no better time to buy oil properties and no better time to hedge oil,” said Dante Caravaggio, President and CEO of the Company. “While we are long-term bullish, this is an election year, which means the markets may see some volatility. We can afford to build an advantageous hedge position, especially since right now EON is at the lower end of our forecasted oil production rate for the current year.”

“EON has successfully used a target hedge price for oil of $60.00 per barrel or greater for the current 2026 and 2027 hedge contracts,” said Mitchell B. Trotter, CFO of the Company. “Our current hedging level positions EON well for potential banking needs, acquisitions, and other growth opportunities.”

“We spent two years stabilizing production and upgrading infrastructure, and we are seeing the positive results of this effort in the last half of 2025,” said Jesse Allen, Vice President of Operations for the Company. “We are now expanding production by tapping into non-producing reserves. We are in a great position to strengthen our hedging program as potentially 92 horizontal wells over the next five years may be drilled under EON’s farmout.”

We encourage EON followers to read our letter to shareholders issued on January 21, 2026 to learn more about 2025 and how EON is positioned for 2026 and beyond. The shareholder letter can be found on the EON website under investor relations.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in a diversified portfolio of long-life producing oil and natural gas properties and other energy holdings. EON’s approach is to build an energy company through acquisition and through selective development of its properties. Class A Common Stock of EON trades on the NYSE American Stock Exchange under the symbol of “EONR” and the Company’s public warrants trade under the symbol of “EONRWS”. For more information on the Company, please visit the EON website.

About the Grayburg-Jackson Field Property

Our Grayburg-Jackson Field (“GJF”) is located on the Northwest Shelf of the Permian Basin in Eddy County, New Mexico. The GJF comprises of 13,700 contiguous leasehold acres where the leasehold rights include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC, estimates proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) is approximately 956 million barrels of oil. The Company has two production programs. The first is the existing waterflood recovery primarily in the Seven Rivers formation via the 550 wells already in place. The second is via a Farmout agreement in the San Andres formation where the recovery will primarily be under the horizontal drilling program that the Company expects to drill up to 90 new wells over the next several years. More information on the property can be located on the Grayburg-Jackson Field page of our website.

About the South Justis Field Property

The South Justis Field (“SJF”) is a carbonate reservoir similar to the rest of the Permian, and is located in Lea County, New Mexico approximately 100 miles from the GJF. The SJF is comprised of 5,360 contiguous acres containing 208 total producing and injection wells with well spacing of 50 acres. The producing formations include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil. More information on the property can be located on the South Justis Field page of our website.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations

Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

WEST PALM BEACH, FLORIDA / ACCESS Newswire / February 12, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), announces the reopening of its experiential USPA Shop Flagship at the USPA National Polo Center (NPC) in Wellington, Florida. The sports brand is introducing a reimagined retail destination that reflects the brand’s deep connection to the sport of polo and its modern global positioning.

The USPA Shop at NPC now places a strong emphasis on the guest experience. Inside and out, the space is complemented by refined visuals, immersive activations, curated sound, a signature scent, and a best-in-class assortment of apparel and accessories from the brand’s design hubs of New York, London, Florence, and Istanbul. The refreshed design of the flagship location blends heritage, sport, and contemporary style, incorporating signature U.S. Polo Assn. elements such as the iconic red, white, and blue stripe, the Double Horsemen logo, and global photo shoot imagery of U.S. Polo Assn. brand ambassadors.

At the center of the store hangs the iconic Halo, a 360-degree digital screen bringing world-class sports content from Florida’s high-goal polo season to life, extending the excitement on the field into the retail environment. New to the store for the season is a branded U.S. Polo Assn. selfie wall, a guest-facing focal point, featuring polo balls, mallets, and authentic game-day props that invite fans to capture and share the spirit of the sport.

“The USPA Shop at NPC is a powerful extension of the U.S. Polo Assn. brand at the center of American polo,” said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. “This reimagined flagship strengthens our presence at the USPA National Polo Center and raises the bar for how fans engage with both the game and the U.S. Polo Assn. brand through a distinctive, elevated retail experience.”

Throughout the winter polo season, the USPA Shop at NPC will host a series of immersive retail activations for event attendees, including artist collaborations, custom product moments, and interactive brand experiences designed to engage fans beyond the field. Guests can also enjoy a complimentary wine tasting every Sunday, currently featuring U.S. Polo Assn.’s Limited-Edition Rosé. This sport-inspired wine is custom-made from vineyards on polo fields of Virginia.

The USPA Shop at NPC features exclusive, limited-edition styles available on-site or online, curated from U.S. Polo Assn.’s Global Collection, The Polo Club Collection, and the USPA Pro Collection, an assortment designed to appeal to every type of fan at NPC. Event-specific collections are also available for shopping, including the historic U.S. Open Polo Championship®, Snow Polo World Cup St. Moritz, and The Palm Beaches Marathon.

“The enhancement of the flagship USPA Shop at NPC allowed us to refine key touchpoints that matter most on a game day-from storytelling and guest engagement to unique products and modern finishes,” said Brian Kaminer, Senior Vice President of Global Retail Product Development at USPA Global. “The shop reflects who we are today as a brand, combining premium fabrics, responsible production, and exclusive small-batch styles that bring the U.S. Polo Assn. brand to life at the USPA National Polo Center.”

In addition to Sundays during the winter polo season from 1:00 to 6:00 pm., the USPA Shop at NPC is open on Fridays from 12:00 to 3:00 p.m., welcoming guests and club members to take home a piece of the sport of polo. Visit the USPA National Polo Center at 3667 120^th Ave. S, Wellington, Florida, 33414.

About U.S. Polo Assn. and USPA Global

U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and located in Wellington, Florida. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.

U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.

USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.

###

For Additional Information, Contact:

Stacey Kovalsky – VP, Global PR and Communications
Phone +954.673.1331 – E-mail: skovalsky@uspagl.com

Kaela Drake – Senior PR and Communications Specialist
Phone +001.561.461.8596 – E-mail: kdrake@uspagl.com

SOURCE: U.S. Polo Assn.

View the original press release on ACCESS Newswire